• 1
    Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65: 965-974.
  • 2
    Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology. 2003; 61: 14-24.
  • 3
    Cox G, Kaplan G, for the American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997; 37: 1035-1041.
  • 4
    Ray ME, Thames HD, Levy LB, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006; 64: 1140-1150.
  • 5
    Horwitz EM, Vicini F, Ziaja EL, et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys. 1996; 36: 565-571.
  • 6
    Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 2002; 2002: 297-303.
  • 7
    DeWitt KD, Sandler HM, Weinberg V, et al. What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer? Urology. 2003; 62: 492-496.
  • 8
    Crook JM, Bahadur YA, Bociek RG, et al. Radiotherapy for localized prostate carcinoma: the correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer. 1997; 79: 328-336.
  • 9
    Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. J Urol. 1996; 156( 2 pt 1): 450-453.
  • 10
    D'Amico AV, Moul J, Carroll PR, et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004; 172: S42-S47.
  • 11
    D'Amico AV, Moul J, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003; 95: 1376-1383.
  • 12
    Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2006; 23: 826-831.
  • 13
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 1591-1597.
  • 14
    Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys. 2008; 70: 59-66.
  • 15
    Buyyounouski MK, Pickles T, Kestin L, Allison R, Williams SG. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 75: S103-S104.
  • 16
    Denham JW, Stiegler A, Wilcox C, et al. Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol. 2008; 9: 1058-1068.
  • 17
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 18
    Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study), a phase III randomized trial. Lancet. 2002; 360: 103.
  • 19
    Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290.
  • 20
    Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008; 26: 585-591.
  • 21
    Moul JW, Banez LL, Freedland SJ. Rising PSA in nonmetastatic prostate cancer. Oncology. 2007; 21: 1436-1454.
  • 22
    Walsh PC, Deweese TL, Eisenberger MA. A structured debate: immediate versus deferred androgen suppression in prostate cancer—evidence for deferred treatment. J Urol. 2001; 166: 508-516.
  • 23
    Souhami L, Bae K, Pilepich M, Sandler H. Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31. Int J Radiat Oncol Biol Phys. 2010; 78: 1301-1306.
  • 24
    Shipley WU, Desilvio M, Pilepich MV, et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: a secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys. 2006; 64: 1162-1167.
  • 25
    Kuban DA, Levy LB, Cheung MR, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011; 79: 1310-1317.
  • 26
    Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer. J Urol. 2008; 180: 1438-1444.
  • 27
    D'Ambrosio DJ, Ruth K, Buyyounouski MK, Horwitz EM, Uzzo RG, Pollack A. Prostate specific antigen kinetics in men treated with radiotherapy and androgen deprivation. Int J Radiat Oncol Biol Phys. 2006; 66: S334-S335.